From HPO
Acute monocytic leukemia- MedGen UID:
- 7319
- •Concept ID:
- C0023465
- •
- Neoplastic Process
The accumulation of transformed primitive hematopoietic blast cells, which lose their ability of normal differentiation and proliferation.
Acute myeloid leukemia- MedGen UID:
- 9730
- •Concept ID:
- C0023467
- •
- Neoplastic Process
A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)
Lymphoma- MedGen UID:
- 44223
- •Concept ID:
- C0024299
- •
- Neoplastic Process
A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells.
Myelodysplasia- MedGen UID:
- 10231
- •Concept ID:
- C0026985
- •
- Congenital Abnormality
Clonal hematopoietic stem cell disorders characterized by dysplasia (ineffective production) in one or more hematopoietic cell lineages, leading to anemia and cytopenia.
Neuroblastoma- MedGen UID:
- 18012
- •Concept ID:
- C0027819
- •
- Neoplastic Process
ALK-related neuroblastic tumor susceptibility is characterized by increased risk for neuroblastic tumors including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Neuroblastoma is a more malignant tumor and ganglioneuroma a more benign tumor. Depending on the histologic findings, ganglioneuroblastoma can behave in a more aggressive fashion, like neuroblastoma, or in a benign fashion, like ganglioneuroma. Preliminary data from the ten reported families with ALK-related neuroblastic tumor susceptibility suggest an overall penetrance of approximately 57% with the risk for neuroblastic tumor development highest in infancy and decreasing by late childhood.
Epistaxis- MedGen UID:
- 4996
- •Concept ID:
- C0014591
- •
- Pathologic Function
Epistaxis, or nosebleed, refers to a hemorrhage localized in the nose.
Thrombocytopenia- MedGen UID:
- 52737
- •Concept ID:
- C0040034
- •
- Disease or Syndrome
A reduction in the number of circulating thrombocytes.
Prolonged bleeding time- MedGen UID:
- 56231
- •Concept ID:
- C0151529
- •
- Finding
Prolongation of the time taken for a standardized skin cut of fixed depth and length to stop bleeding.
Impaired platelet aggregation- MedGen UID:
- 383786
- •Concept ID:
- C1855853
- •
- Finding
An impairment in the rate and degree to which platelets aggregate after the addition of an agonist that stimulates platelet clumping. Platelet aggregation is measured using aggregometer to measure the optical density of platelet-rich plasma, whereby platelet aggregation causes the plasma to become more transparent.
Abnormal dense granule content- MedGen UID:
- 867462
- •Concept ID:
- C4021839
- •
- Anatomical Abnormality
A deviation from the normal contents of the platelet alpha granules, which normally contain adenosine triphosphate (ATP), adenosine diphosphate (ADP), serotonin, calcium, and pyrophosphate, which are secreted when platelets are activated.
Abnormal alpha granule content- MedGen UID:
- 868469
- •Concept ID:
- C4022863
- •
- Anatomical Abnormality
A deviation from the normal contents of the platelet alpha granules, which normally contain hemostatic proteins such as fibrinogen, von Willebrand factor, and growth factors such as platelet-derived growth factor.
Abnormal platelet shape- MedGen UID:
- 868472
- •Concept ID:
- C4022866
- •
- Anatomical Abnormality
A deviation from the normal discoid platelet shape.
Impaired arachidonic acid-induced platelet aggregation- MedGen UID:
- 868750
- •Concept ID:
- C4023155
- •
- Pathologic Function
Abnormal response to arachidonic acid as manifested by reduced or lacking aggregation of platelets upon addition of arachidonic acid.
Impaired collagen-induced platelet aggregation- MedGen UID:
- 870264
- •Concept ID:
- C4024703
- •
- Finding
Abnormal response to collagen or collagen-mimetics as manifested by reduced or lacking aggregation of platelets upon addition collagen or collagen-mimetics.
Impaired ADP-induced platelet aggregation- MedGen UID:
- 870824
- •Concept ID:
- C4025282
- •
- Finding
Abnormal platelet response to ADP as manifested by reduced or lacking aggregation of platelets upon addition of ADP.
Ecchymosis- MedGen UID:
- 8524
- •Concept ID:
- C0013491
- •
- Finding
A purpuric lesion that is larger than 1 cm in diameter.
Petechiae- MedGen UID:
- 10680
- •Concept ID:
- C0031256
- •
- Disease or Syndrome
Petechiae are pinpoint-sized reddish/purple spots, resembling a rash, that appear just under the skin or a mucous membrane when capillaries have ruptured and some superficial bleeding into the skin has happened. This term refers to an abnormally increased susceptibility to developing petechiae.
Purpura- MedGen UID:
- 19584
- •Concept ID:
- C0034150
- •
- Disease or Syndrome
Purpura (from Latin
Bruising susceptibility- MedGen UID:
- 140849
- •Concept ID:
- C0423798
- •
- Finding
An ecchymosis (bruise) refers to the skin discoloration caused by the escape of blood into the tissues from ruptured blood vessels. This term refers to an abnormally increased susceptibility to bruising. The corresponding phenotypic abnormality is generally elicited on medical history as a report of frequent ecchymoses or bruising without adequate trauma.
- Abnormality of blood and blood-forming tissues
- Abnormality of the integument
- Neoplasm